Canada markets closed
  • S&P/TSX

    20,402.66
    -59.24 (-0.29%)
     
  • S&P 500

    4,455.48
    +6.50 (+0.15%)
     
  • DOW

    34,798.00
    +33.20 (+0.10%)
     
  • CAD/USD

    0.7904
    +0.0002 (+0.02%)
     
  • CRUDE OIL

    74.43
    +0.45 (+0.61%)
     
  • BTC-CAD

    55,268.30
    +893.43 (+1.64%)
     
  • CMC Crypto 200

    1,067.20
    -35.86 (-3.25%)
     
  • GOLD FUTURES

    1,750.70
    -1.00 (-0.06%)
     
  • RUSSELL 2000

    2,248.07
    -10.97 (-0.49%)
     
  • 10-Yr Bond

    1.4600
    +0.0500 (+3.55%)
     
  • NASDAQ futures

    15,319.50
    +0.75 (+0.00%)
     
  • VOLATILITY

    17.75
    -0.88 (-4.72%)
     
  • FTSE

    7,051.48
    -26.87 (-0.38%)
     
  • NIKKEI 225

    30,248.81
    +609.41 (+2.06%)
     
  • CAD/EUR

    0.6741
    +0.0014 (+0.21%)
     

Stocks in play: Numinus Wellness Inc.

  • Oops!
    Something went wrong.
    Please try again later.
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Announced that Health Canada has cleared the MAPS-sponsored single-arm, open-label safety and feasibility study evaluating MDMA-assisted therapy for post-traumatic stress disorder (PTSD). This study is being pursued in collaboration with MAPS Public Benefit Corporation (MAPS PBC), a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), the leading developer of MDMA-assisted therapy training programs, treatment protocols and research. Numinus Wellness Inc. shares V.NUMI are trading up 11 cents at $1.13.

Read:

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting